Many respiratory diseases are driven by a cycle of infection, damage caused by mechanical ventilation and inflammation creating repeated injury to the body. Today, there are limited therapeutic and preventive options designed to address these conditions known to seriously impact health, especially the health of our most vulnerable populations.
Based on preclinical data, zelpultide alfa (AT-100) may have the potential to reach a broad range of patients living with serious respiratory diseases and inflammatory diseases outside of the lung, including:
- COVID19
- Influenza
- RSV
- Other respiratory diseases
- Inflammatory diseases outside the lung
